Entero Therapeutics, Inc. Common Stock
Symbol: ENTO (NASDAQ)
Company Description:
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
- Today's Open: $4.65
- Today's High: $7.496
- Today's Low: $4.086
- Today's Volume: 3.58M
- Yesterday Close: $5
- Yesterday High: $5.06
- Yesterday Low: $4.7
- Yesterday Volume: 129.36K
- Last Min Volume: 2.66K
- Last Min High: $4.334
- Last Min Low: $4.294
- Last Min VWAP: $4.30476
- Name: Entero Therapeutics, Inc. Common Stock
- Website: https://www.enterothera.com
- Listed Date: 2016-10-11
- Location: BOCA RATON, FL
- Market Status: Active
- CIK Number: 0001604191
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $7.94M
- Round Lot: 100
- Outstanding Shares: 1.59M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-09-26 | SEC STAFF ACTION | View |
2025-09-17 | 424B3 | View |
2025-09-15 | EFFECT | View |
2025-09-12 | 8-K | View |
2025-09-10 | S-1/A | View |
2025-09-09 | 8-K | View |
2025-08-26 | S-1 | View |
2025-08-26 | PRE 14A | View |
2025-08-18 | 3 | View |
2025-08-18 | 3 | View |
2025-08-18 | D | View |
2025-08-15 | 8-K | View |
2025-08-14 | 10-Q | View |
2025-08-11 | 8-K | View |
2025-07-16 | 8-K | View |
2025-07-08 | 8-K | View |
2025-07-02 | S-1/A | View |
2025-07-02 | 8-K | View |
2025-06-30 | 8-K | View |
2025-06-23 | S-1/A | View |